Subcutaneous Infusion News and Research

RSS
Wearable delivery device allows adults with type 2 diabetes to safely use affordable insulin therapy

Wearable delivery device allows adults with type 2 diabetes to safely use affordable insulin therapy

Enable Injections enters into a development agreement with Genentech

Enable Injections enters into a development agreement with Genentech

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

Apomorphine infusion found to be effective treatment for Parkinson’s patients with motor fluctuations

Apomorphine infusion found to be effective treatment for Parkinson’s patients with motor fluctuations

Study shows evidence that old drug may provide relief for advanced Parkinson's disease patients

Study shows evidence that old drug may provide relief for advanced Parkinson's disease patients

New infusion therapy may help avoid debilitating symptoms in Parkinson's disease patients

New infusion therapy may help avoid debilitating symptoms in Parkinson's disease patients

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

BD Saf-T-Intima Safety Integrated IV Catheter System gets European approval for subcutaneous infusion therapy

BD Saf-T-Intima Safety Integrated IV Catheter System gets European approval for subcutaneous infusion therapy

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Positive results from Nile's cenderitide Phase 1 trial on chronic heart failure

Long-term data from Baxter's HyQ clinical study on PI

Long-term data from Baxter's HyQ clinical study on PI

Nile Therapeutics third quarter net loss decreases to $1.1 million

Nile Therapeutics third quarter net loss decreases to $1.1 million

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Infusion nurses examine need for standards of practice in immunoglobulin therapy

Infusion nurses examine need for standards of practice in immunoglobulin therapy

FDA approves Remodulin for the treatment of pulmonary arterial hypertension

FDA approves Remodulin for the treatment of pulmonary arterial hypertension